You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug [see all tables in this series...]

Part (ii) All clients with opioids as primary drug type: number of episodes reporting the stated drugs as secondary

Country	Opioids	Cocaine	Other stimulants	Hypnotics/sedatives	Hallucinogens	Volatile substances	Cannabis	Alcohol	Others	Total
Bulgaria	49	33	35	9	0	1	170	8	6	311
Czech Republic	110	7	233	34	2	3	134	13	2	538
Denmark	48	24	4	59	2	0	249	0	735	1121
Germany	32595	1169	1435	1112	488	39	3308	6498	144	46788
Ireland	366	658	123	734	17	4	810	226	3	2941
Greece	39	563	211	766	117	4	1091	91	35	2917
France	608	1051	162	266	38	15	1091	398	43	3672
Italy	509	7118	1040	645	355	62	6620	2238	275	18862
Cyprus	6	34	10	12	5		66	1	1	135
Malta	0	206	130	37	40	1	248	1		663
Netherlands	384	1034	17	83	0	0	126	231	21	1896
Slovakia	7	16	160	26	10	10	102	14	1	346
Finland	66	1	193	203						463
United Kingdom	4961	14889	1138	5275	28	15	5515	2608	191	34620
Total	39748	26803	4891	9261	1102	154	19530	12327	1457	115273

Notes:

Data on secondary drug use are only collected among all treatment clients and not separately for new treatment clients.

'Opioids' include: heroin, methadone, other opioids; 'Cocaine' includes: cocaine HCl, crack cocaine; 'Stimulants' include: amphetamines, MDMA and derivates, other stimulants: 'Cannabis' can include herb or resin. For each client up to four secondary drugs can be reported.

A number of the clients report using the same drug both as primary and secondary drug, particularly for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI protocol for the drugs categories.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

2006 Reitox national reports.